New clinical trial focused on pulmonary complications in COVID-19 patients
The Montreal Heart Institute has launched a new clinical trial aimed at improving care for patients who have been diagnosed with COVID-19.
The COLCORONA trial is the work of the Montreal Health Innovations Coordinating Center, with support coming from Pharmascience, CGI and Quebec’s government. The goal is to recruit approximately 6,000 participants and see if the proposed treatment could severe pulmonary complications—such as major inflammatory storm—and deaths associated with COVID-19.
Patients are eligible for the COLCORONA trial if they have a positive diagnosis for COVID-19, are over the age of 40 and have not yet been hospitalized. Each participant will take either a drug or a placebo each day for a total of 30 days.
“Women who do not take contraceptives, those who are pregnant and those who are breastfeeding are not eligible for the clinical study,” according to a statement from the Montreal Heart Institute.
More information about the COLCORONA clinical trial, including contact information, is available here.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.